CHMP positive opinion regarding Somatropin Biopartners

Biopartners GmbH, a wholly owned subsidiary of Bioton SA, Poland, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion regarding the approval of once-weekly Somatropin Biopartners for the treatment of growth hormone deficiency (GHD) in paediatric and adult patients.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Source Type: news